PRANAZEPIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C26H19FN4O2
Molecular Weight	438.4531
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=C(C=CC=C1)C2=N[C@H](NC(=O)C3=CC4=C(N3)C=CC=C4)C(=O)N5CCC6=C5C2=CC=C6

InChI

InChIKey=WKJDXKWFGJWGAS-XMMPIXPASA-N

InChI=1S/C26H19FN4O2/c27-19-10-3-2-8-17(19)22-18-9-5-7-15-12-13-31(23(15)18)26(33)24(29-22)30-25(32)21-14-16-6-1-4-11-20(16)28-21/h1-11,14,24,28H,12-13H2,(H,30,32)/t24-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://adisinsight.springer.com/drugs/800003071https://www.ncbi.nlm.nih.gov/pubmed/7805132
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8680546

(R)-FK480 is enantiomer of a cholecystokin-type-A (CCK-A) receptor antagonist FK480. Binding of (R)-FK480 to CCK-A is 26 times less potent than (S)-FK480.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://adisinsight.springer.com/drugs/800003071 \| https://www.ncbi.nlm.nih.gov/pubmed/7805132	Antagonist 2849		0.4 nM [IC50]
Cholecystokinin A receptor 7 Target ID: CHEMBL1901 Sources: http://www.ncbi.nlm.nih.gov/pubmed/7805132	Binding Agent 1076		18.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pancreatitis 16 Sources: http://adisinsight.springer.com/drugs/800003071	Primary		Phase II 1147	Unknown Approved Use Unknown
Unknown 2596

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.005% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560875/			PRANAZEPIDE plasma	Homo sapiens

PubMed

Title	Date	PubMed
Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK-480. Synthesis and structure-activity relationships of FK-480 and related compounds.	1994-10	7805132
Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.	1994-02	7509389

Patents

Sample Use Guides

In Vivo Use Guide

Rats: FK480 (PRANAZEPIDE) inhibited pancreatic exocrine secretion dose dependently at doses of 0.01-1.0 mg/kg.

Route of Administration: Oral

In Vitro Use Guide

PRANAZEPIDE (10 nM) blocked calcium oscillation induced by CCK (10 pM) in isolated rat pancreatic acini..

Name

Type

Language

PANAZEPIDE

Preferred Name

English

PRANAZEPIDE

Official Name

English

pranazepide [INN]

Common Name

English

PANAZEPIDE [JAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C547